This session will present new data from recent clinical research in cystic fibrosis. Presentations will include assessment of measures of disease progression, new data on the effects of CFTR potentiators and correctors in younger patients and over longer time spans, and studies of the correlation between in vitro and in vivo responses to CFTR potentiators.
Compare outcome parameters and clinical trials results in
infants and preschool children.
Analyze the impact of CFTR modifiers in younger patients and
over longer time spans.
Examine the correlation between ex vivo and in vivo drug